clinical trial · NCT04701164
Efficacy and Safety of ANX005 in Subjects With Guillain-Barré Syndrome
Guillain-Barre SyndromeANX005Placebo
brief summary
This study is intended to evaluate the efficacy and safety of ANX005 administered by intravenous (IV) infusion to participants recently diagnosed with Guillain-Barré Syndrome (GBS). The total duration of study participation is approximately 6 months.
started
Dec 17, 2020
primary completion
Apr 20, 2024
completion
Apr 20, 2024
last updated
May 29, 2025
official title
A Randomized, Double-blind, Placebo-controlled Phase 3 Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of ANX005 in Subjects With Guillain-Barré Syndrome
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol